WMS 2021 on Thursday, September 23rd was a full day of oral and poster presentations, and we’ll highlight some Duchenne clinical trial updates covered. Solid Biosciences – SGT-001 micro-dystrophin gene […]
WMS 2021’s agenda on Wednesday, September 22nd was not so much about specific diseases, but rather major and timely research themes across all of biology. The day started with a […]
Monday, September 20th was the first day of the WMS 2021 Virtual Congress, and a day devoted to symposia sponsored by various companies developing therapeutic treatments for neuromuscular disorders. Most […]
It’s that time of year again, when neuromuscular disease researchers clear their calendars for the Annual International Congress of the World Muscle Society (WMS), the largest conference focused solely on […]
CureDuchenne Cares Advocacy Efforts Succeed in Adding Duchenne to the Social Security Administration Compassionate Allowance List (CAL) Social Security Disability Insurance (SSDI) benefits are a financial lifeline for millions of […]
With recent clinical updates from Pfizer, Sarepta and Audenteson their programs in muscular disorders, the timely Gene Therapy for Muscular Disorders arrives as the only meeting dedicated to overcoming the translational […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
Built by the community, for the community, the DuchenneXchange has offered a secure place to inform, inspire and empower those living with Duchenne since its inception in 2018. By offering […]
CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from […]
